Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders.

Authors

• Saadia Sherazi
• Susan Schleede
• Scott McNitt
• Carla Casulo
• Jeremiah E Moore
• Eugene Storozynsky
• Arpan Patel
• Neelima Vidula
• Mehmet K Aktas
• Clive S Zent
• Ilan Goldenberg

Publication/Presentation Date

3-21-2023

Abstract

Background There are limited data on risk of arrhythmias among patients with lymphoproliferative disorders. We designed this study to determine the risk of atrial and ventricular arrhythmia during treatment of lymphoma in a real-world setting. Methods and Results The study population comprised 2064 patients included in the University of Rochester Medical Center Lymphoma Database from January 2013 to August 2019. Cardiac arrhythmias-atrial fibrillation/flutter, supraventricular tachycardia, ventricular arrhythmia, and bradyarrhythmia-were identified using

Volume

12

Issue

6

First Page

025786

Last Page

025786

ISSN

2047-9980

Published In/Presented At

Sherazi, S., Schleede, S., McNitt, S., Casulo, C., Moore, J. E., Storozynsky, E., Patel, A., Vidula, N., Aktas, M. K., Zent, C. S., & Goldenberg, I. (2023). Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders. Journal of the American Heart Association, 12(6), e025786. https://doi.org/10.1161/JAHA.122.025786

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

36892046

Department(s)

Administration and Leadership

Document Type

Article